Hormone replacement therapy, heart disease, and other considerations

Annual Review of Public Health

Volumn 19, Issue , 1998, Pages 55-72

  Barrett Connor, Elizabeth ^a   Grady, Deborah ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Estrogen; Heart disease; Meta analysis; Osteoporosis

Indexed keywords

ESTROGEN; GESTAGEN;

AGED; BREAST CANCER; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; GALLBLADDER DISEASE; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM;

BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; CORONARY DISEASE; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GALLBLADDER DISEASES; HUMANS; PROGESTINS; RISK ASSESSMENT; THROMBOPHLEBITIS; UNITED STATES; WOMEN'S HEALTH;

EID: 0031866317     PISSN: 01637525     EISSN: None     Source Type: Journal    
DOI: 10.1146/annurev.publhealth.19.1.55     Document Type: Review

References (20)

1. Adam S, Williams V, Vessey M. 1981. Cardiovascular disease and hormone replacement treatment: a pilot case-control study. Br. Med. J. 282:1277-78
2. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, et al. 1990. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10:1051-57
3. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. 1997. Medroxyprogesterone acetate antagonizes inhibitor effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:217-21
4. Archer D, Pickar J, Bottiglioni F. 1994. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet. Gynecol. 83:686-92
5. Armstrong B. 1988. Oestrogen therapy after the menopause - boon or bane? Med. J. Aust. 148:213-14
6. Bain C, Willett W, Hennekens C, Rosner B, Belanger C, et al. 1981. Use of pos-tmenopausal hormones and risk of myocardial infarction. Circulation 64:42-46
7. Barrett-Connor E. 1991. Postmenopausal estrogen and prevention bias. Ann. Intern. Med. 115:455-56
8. Barrett-Connor E. 1992. Hormone replacement and cancer. Br. Med. Bull. 4:345-55
9. Barrett-Connor E. 1994. Postmenopausal estrogen and the risk of breast cancer. Ann. Epidemiol. 4:177-80
10. Barrett-Connor E, Bush TL. 1991. Estrogen and coronary heart disease in women. JAMA. 265:1861-67
11. Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, et al. 1997. The postmenopausal estrogen/progestin interventions (PEPI) study: primary outcomes in adherent women. Maturitas 27:261-74
12. Barrett-Connor E, Wilcosky T, Wallace RB, Heiss G. 1986. Resting and exercise electrocardiographic abnormalities associated with sex hormone use in women: The Lipid Research Clinics Program Prevalence Study. Am. J. Epidemiol. 123:81-88
13. Beard CM, Kottke TE, Annegers JF, Ballard DJ. 1989. The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year-old women, 1960 through 1982. Mayo Clin. Proc. 64:1471-80
14. Beresford SA, Weiss NS, Voigt LF, McKnight B. 1997. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349:458-61
15. Bergkvist L, Adami H, Persson I, Hoover R, Schairer C. 1989. The risk of breast cancer after estrogen and estrogen-progestin replacement. N. Engl. J. Med. 321: 293-97
16. Herman RS, Epstein RS, Lydick E. 1997. Risk factors associated with women's compliance with estrogen replacement therapy. J. Women's Health 6:219-26
17. Boston Collaborative Drug Surveillance Program. 1974. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N. Engl. J. Med. 290:15-19
18. Boyd NF, Byng JW. Jong RA, Fishell EK, Little LE, et al. 1995. Quantitative classification of mammographic densities and breast cancer risk-results from the Canadian National Breast Screening Study. J. Natl. Cancer Inst. 87:670-75
19. Brett KM, Madans JH. 1997. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am. J. Epidemiol. 145:536-45
20. Brinton L, Hoover R, Fraumeni J. 1986. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br. J. Cancer 54:825-32